Wockhardt Limited
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments).
What Wockhardt files
- Others57
- Updates31
- Board Meeting9
- Investor Meet6
- Important4
- PPTs3
Wockhardt Bio AG has incorporated a new wholly owned subsidiary named Wockhardt Antibiotics (Ireland) Limited, marking its expansion into the European Union's pharmaceutical market. The newly formed entity, holding a capital of 100 Euro, will help facilitate the distribution of Wockhardt's antibiotic products across the EU. This strategic move aligns...
Wockhardt Limited has announced a board meeting to approve the financial results for the quarter and nine months ended December 31, 2024. **Consolidated Financials**: Total income for the quarter reached ₹729 crore, a decrease of 8% year-over-year. For the nine months, income was ₹2,316 crore, up from ₹2,129 crore in...
Consolidated financial results show total income of ₹1,587 crore for the half-year, reflecting a year-over-year growth driven by strong demand and operational expansion. Despite the revenue growth, the company recorded a net loss of ₹333 crore, indicating pressures from operational costs and a challenging market environment. Earnings per share (EPS)...
Wockhardt Limited has released its latest Investor Presentation, highlighting a remarkable 76% year-on-year growth in EBITDA and a 14% increase in total income to INR 2,879 Cr. The company is focusing on combating antimicrobial resistance with its novel antibiotics, ZAYNICH® and MIQNAF®, and anticipates strong growth in biosimilars, especially diabetes-related...